A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Recruiting

Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Sponsor:

Pfizer

Code:

NCT05355701

Conditions

Melanoma

Non-Small-Cell Lung Cancer

Thyroid Cancer

Glioma

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

PF-07799933

binimetinib

cetuximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information